{"id":4641,"date":"2001-07-30T18:52:47","date_gmt":"2001-07-30T17:52:47","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4641"},"modified":"2014-06-11T17:30:40","modified_gmt":"2014-06-11T17:30:40","slug":"bristol-myers-squibb-agrees-to-purchase-duponts-drug-business","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4641","title":{"rendered":"Bristol-Myers Squibb agrees to purchase DuPont&#8217;s drug business"},"content":{"rendered":"<p><strong>Drug manufacturer Bristol-Myers Squibb agreed yesterday to purchase DuPont Co.&#8217;s drug business for $7.8 billion, a deal that would boost Bristol-Myers&#8217; line of AIDS drugs, the Washington Post reports.<\/strong><\/p>\n<p>Among other drugs, Bristol-Myers will acquire DuPont&#8217;s best-selling AIDS drug Sustiva &#8211; a component of some triple-combination drug therapies &#8211; which garnered $386 million in sales last year for DuPont (Washington Post, 08\/06). In addition, DuPont has three AIDS drugs in development. Bristol-Myers manufactures the AIDS drugs Zerit and Videx &#8211; both also drugs used in some three-drug therapies &#8211; and also has new AIDS therapies under development. AIDS advocates, who plan to file a protest of the consolidation with the FTC, say it will lead to decreased competition and fuel higher AIDS drug prices.<\/p>\n<p>However, Bristol-Myers spokesperson Charles Borgognoni said the company believes the AIDS drug production market will remain equally competitive following the consolidation. &#8220;Our perspective going into the deal is we don&#8217;t expect there will be any overt regulatory problems,&#8221; he said. The deal still requires regulatory approval, and is expected to be completed by the end of the year (Clendenning, Associated Press, 08\/06).<\/p>\n<p>Source: Kaiser Daily HIV\/AIDS Reports<\/p>\n<p><a href=\"http:\/\/www.kaisernetwork.org\">http:\/\/www.kaisernetwork.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug manufacturer Bristol-Myers Squibb agreed yesterday to purchase DuPont Co.&#8217;s drug business for $7.8 billion, a deal that would boost Bristol-Myers&#8217; line of AIDS drugs, the Washington Post reports. Among other drugs, Bristol-Myers will acquire DuPont&#8217;s best-selling AIDS drug Sustiva &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-4641","post","type-post","status-publish","format-standard","hentry","category-other-news"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4641"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4641\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}